Do analysts rate XTLB or GRML?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score XTL Biopharmaceuticals 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Greenland Mines Ltd. Common Stock 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Is XTLB or GRML more profitable?

XTL Biopharmaceuticals' return on equity of 0.00% beat Greenland Mines Ltd. Common Stock's return on equity. Company Net Margins Return on Equity Return on Assets XTL Biopharmaceuticals N/A N/A N/A Greenland Mines Ltd. Common Stock N/A -109.40% -98.80%

Does the media refer more to XTLB or GRML?

In the previous week, XTL Biopharmaceuticals and XTL Biopharmaceuticals both had 1 articles in the media. Greenland Mines Ltd. Common Stock's average media sentiment score of 0.39 beat XTL Biopharmaceuticals' score of 0.00 indicating that Greenland Mines Ltd. Common Stock is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment XTL Biopharmaceuticals 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Greenland Mines Ltd. Common Stock 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Do analysts prefer XTLB or MRKR?

Marker Therapeutics has a consensus target price of $10.00, suggesting a potential upside of 680.64%. Given Marker Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Marker Therapeutics is more favorable than XTL Biopharmaceuticals. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score XTL Biopharmaceuticals 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Marker Therapeutics 1 Sell rating(s) 1 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.25

Do analysts prefer XTLB or VYNE?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score XTL Biopharmaceuticals 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 VYNE Therapeutics 1 Sell rating(s) 3 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.75

Does the media refer more to XTLB or VYNE?

In the previous week, VYNE Therapeutics had 3 more articles in the media than XTL Biopharmaceuticals. MarketBeat recorded 4 mentions for VYNE Therapeutics and 1 mentions for XTL Biopharmaceuticals. XTL Biopharmaceuticals' average media sentiment score of 0.00 beat VYNE Therapeutics' score of -0.30 indicating that XTL Biopharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment XTL Biopharmaceuticals 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral VYNE Therapeutics 0 Very Positive mention(s) 2 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Do analysts recommend XTLB or TXMD?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score XTL Biopharmaceuticals 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 TherapeuticsMD 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Do analysts prefer XTLB or NCEL?

NLS Pharmaceutics has a consensus price target of $23.00, suggesting a potential upside of 518.28%. Given NLS Pharmaceutics' stronger consensus rating and higher probable upside, analysts plainly believe NLS Pharmaceutics is more favorable than XTL Biopharmaceuticals. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score XTL Biopharmaceuticals 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 NLS Pharmaceutics 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00

Which has higher earnings and valuation, XTLB or NCEL?

XTL Biopharmaceuticals has higher revenue and earnings than NLS Pharmaceutics. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio XTL Biopharmaceuticals $450K 13.79 -$6.97M -$0.64 N/A NLS Pharmaceutics N/A N/A -$8.30M N/A N/A

Is XTLB or NCEL more profitable?

Company Net Margins Return on Equity Return on Assets XTL Biopharmaceuticals N/A N/A N/A NLS Pharmaceutics N/A N/A N/A

XTL Biopharmaceuticals (XTLB) Competitors

$2.82 -0.10 (-3.42%)

As of 12:48 PM Eastern

Compare

XTLB vs. GRML, MRKR, VYNE, TXMD, and NCEL

Should you buy XTL Biopharmaceuticals stock or one of its competitors? MarketBeat compares XTL Biopharmaceuticals with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with XTL Biopharmaceuticals include Greenland Mines Ltd. Common Stock (GRML), Marker Therapeutics (MRKR), VYNE Therapeutics (VYNE), TherapeuticsMD (TXMD), and NLS Pharmaceutics (NCEL). These companies are all part of the "med - drugs" industry.

How does XTL Biopharmaceuticals compare to Greenland Mines Ltd. Common Stock?

XTL Biopharmaceuticals (NASDAQ:XTLB) and Greenland Mines Ltd. Common Stock (NASDAQ:GRML) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their dividends, profitability, analyst recommendations, institutional ownership, earnings, valuation, risk and media sentiment.

XTL Biopharmaceuticals' return on equity of 0.00% beat Greenland Mines Ltd. Common Stock's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
XTL Biopharmaceuticals	N/A	N/A	N/A
Greenland Mines Ltd. Common Stock	N/A	-109.40%	-98.80%

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
XTL Biopharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Greenland Mines Ltd. Common Stock	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

XTL Biopharmaceuticals has higher revenue and earnings than Greenland Mines Ltd. Common Stock. XTL Biopharmaceuticals is trading at a lower price-to-earnings ratio than Greenland Mines Ltd. Common Stock, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
XTL Biopharmaceuticals	$450K	13.79	-$6.97M	-$0.64	N/A
Greenland Mines Ltd. Common Stock	N/A	N/A	-$10.55M	-$0.32	N/A

4.4% of XTL Biopharmaceuticals shares are held by institutional investors. Comparatively, 20.1% of Greenland Mines Ltd. Common Stock shares are held by institutional investors. 29.0% of XTL Biopharmaceuticals shares are held by company insiders. Comparatively, 11.3% of Greenland Mines Ltd. Common Stock shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

XTL Biopharmaceuticals has a beta of 1.45, indicating that its stock price is 45% more volatile than the broader market. Comparatively, Greenland Mines Ltd. Common Stock has a beta of 7.05, indicating that its stock price is 605% more volatile than the broader market.

In the previous week, XTL Biopharmaceuticals and XTL Biopharmaceuticals both had 1 articles in the media. Greenland Mines Ltd. Common Stock's average media sentiment score of 0.39 beat XTL Biopharmaceuticals' score of 0.00 indicating that Greenland Mines Ltd. Common Stock is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
XTL Biopharmaceuticals	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Greenland Mines Ltd. Common Stock	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

XTL Biopharmaceuticals and Greenland Mines Ltd. Common Stock tied by winning 5 of the 10 factors compared between the two stocks.

How does XTL Biopharmaceuticals compare to Marker Therapeutics?

XTL Biopharmaceuticals (NASDAQ:XTLB) and Marker Therapeutics (NASDAQ:MRKR) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their dividends, risk, analyst recommendations, valuation, institutional ownership, profitability, media sentiment and earnings.

XTL Biopharmaceuticals has a net margin of 0.00% compared to Marker Therapeutics' net margin of -343.03%. XTL Biopharmaceuticals' return on equity of 0.00% beat Marker Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
XTL Biopharmaceuticals	N/A	N/A	N/A
Marker Therapeutics	-343.03%	-73.29%	-59.70%

XTL Biopharmaceuticals has higher earnings, but lower revenue than Marker Therapeutics. XTL Biopharmaceuticals is trading at a lower price-to-earnings ratio than Marker Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
XTL Biopharmaceuticals	$450K	13.79	-$6.97M	-$0.64	N/A
Marker Therapeutics	$3.55M	6.02	-$12.16M	-$0.61	N/A

4.4% of XTL Biopharmaceuticals shares are owned by institutional investors. Comparatively, 22.4% of Marker Therapeutics shares are owned by institutional investors. 29.0% of XTL Biopharmaceuticals shares are owned by insiders. Comparatively, 5.7% of Marker Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

XTL Biopharmaceuticals has a beta of 1.45, suggesting that its share price is 45% more volatile than the broader market. Comparatively, Marker Therapeutics has a beta of 1.45, suggesting that its share price is 45% more volatile than the broader market.

Marker Therapeutics has a consensus target price of $10.00, suggesting a potential upside of 680.64%. Given Marker Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Marker Therapeutics is more favorable than XTL Biopharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
XTL Biopharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Marker Therapeutics	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25

In the previous week, XTL Biopharmaceuticals had 1 more articles in the media than Marker Therapeutics. MarketBeat recorded 1 mentions for XTL Biopharmaceuticals and 0 mentions for Marker Therapeutics. XTL Biopharmaceuticals' average media sentiment score of 0.00 equaled Marker Therapeutics'average media sentiment score.

Company	Overall Sentiment
XTL Biopharmaceuticals	Neutral
Marker Therapeutics	Neutral

Summary

XTL Biopharmaceuticals and Marker Therapeutics tied by winning 7 of the 14 factors compared between the two stocks.

How does XTL Biopharmaceuticals compare to VYNE Therapeutics?

XTL Biopharmaceuticals (NASDAQ:XTLB) and VYNE Therapeutics (NASDAQ:VYNE) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their analyst recommendations, media sentiment, institutional ownership, profitability, valuation, dividends, earnings and risk.

XTL Biopharmaceuticals has a net margin of 0.00% compared to VYNE Therapeutics' net margin of -4,726.21%. XTL Biopharmaceuticals' return on equity of 0.00% beat VYNE Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
XTL Biopharmaceuticals	N/A	N/A	N/A
VYNE Therapeutics	-4,726.21%	-70.42%	-63.46%

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
XTL Biopharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
VYNE Therapeutics	1 Sell rating(s)	3 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.75

4.4% of XTL Biopharmaceuticals shares are owned by institutional investors. Comparatively, 83.8% of VYNE Therapeutics shares are owned by institutional investors. 29.0% of XTL Biopharmaceuticals shares are owned by company insiders. Comparatively, 3.0% of VYNE Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

XTL Biopharmaceuticals has a beta of 1.45, suggesting that its share price is 45% more volatile than the broader market. Comparatively, VYNE Therapeutics has a beta of 2, suggesting that its share price is 100% more volatile than the broader market.

XTL Biopharmaceuticals has higher earnings, but lower revenue than VYNE Therapeutics. XTL Biopharmaceuticals is trading at a lower price-to-earnings ratio than VYNE Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
XTL Biopharmaceuticals	$450K	13.79	-$6.97M	-$0.64	N/A
VYNE Therapeutics	$570K	50.95	-$26.48M	-$0.38	N/A

In the previous week, VYNE Therapeutics had 3 more articles in the media than XTL Biopharmaceuticals. MarketBeat recorded 4 mentions for VYNE Therapeutics and 1 mentions for XTL Biopharmaceuticals. XTL Biopharmaceuticals' average media sentiment score of 0.00 beat VYNE Therapeutics' score of -0.30 indicating that XTL Biopharmaceuticals is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
XTL Biopharmaceuticals	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
VYNE Therapeutics	0 Very Positive mention(s)	2 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

VYNE Therapeutics beats XTL Biopharmaceuticals on 8 of the 14 factors compared between the two stocks.

How does XTL Biopharmaceuticals compare to TherapeuticsMD?

XTL Biopharmaceuticals (NASDAQ:XTLB) and TherapeuticsMD (NASDAQ:TXMD) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, institutional ownership, media sentiment, risk, valuation, dividends, profitability and analyst recommendations.

TherapeuticsMD has a net margin of 5.34% compared to XTL Biopharmaceuticals' net margin of 0.00%. TherapeuticsMD's return on equity of 0.32% beat XTL Biopharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
XTL Biopharmaceuticals	N/A	N/A	N/A
TherapeuticsMD	5.34%	0.32%	0.23%

TherapeuticsMD has higher revenue and earnings than XTL Biopharmaceuticals. XTL Biopharmaceuticals is trading at a lower price-to-earnings ratio than TherapeuticsMD, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
XTL Biopharmaceuticals	$450K	13.79	-$6.97M	-$0.64	N/A
TherapeuticsMD	$3.02M	7.85	-$570K	$0.06	34.17

XTL Biopharmaceuticals has a beta of 1.45, meaning that its stock price is 45% more volatile than the broader market. Comparatively, TherapeuticsMD has a beta of 0.59, meaning that its stock price is 41% less volatile than the broader market.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
XTL Biopharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
TherapeuticsMD	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

4.4% of XTL Biopharmaceuticals shares are owned by institutional investors. Comparatively, 30.7% of TherapeuticsMD shares are owned by institutional investors. 29.0% of XTL Biopharmaceuticals shares are owned by insiders. Comparatively, 1.7% of TherapeuticsMD shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

In the previous week, XTL Biopharmaceuticals had 1 more articles in the media than TherapeuticsMD. MarketBeat recorded 1 mentions for XTL Biopharmaceuticals and 0 mentions for TherapeuticsMD. XTL Biopharmaceuticals' average media sentiment score of 0.00 equaled TherapeuticsMD'saverage media sentiment score.

Company	Overall Sentiment
XTL Biopharmaceuticals	Neutral
TherapeuticsMD	Neutral

Summary

TherapeuticsMD beats XTL Biopharmaceuticals on 8 of the 12 factors compared between the two stocks.

How does XTL Biopharmaceuticals compare to NLS Pharmaceutics?

XTL Biopharmaceuticals (NASDAQ:XTLB) and NLS Pharmaceutics (NASDAQ:NCEL) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their media sentiment, analyst recommendations, institutional ownership, dividends, earnings, risk, valuation and profitability.

Company	Net Margins	Return on Equity	Return on Assets
XTL Biopharmaceuticals	N/A	N/A	N/A
NLS Pharmaceutics	N/A	N/A	N/A

4.4% of XTL Biopharmaceuticals shares are owned by institutional investors. 29.0% of XTL Biopharmaceuticals shares are owned by insiders. Comparatively, 16.4% of NLS Pharmaceutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

XTL Biopharmaceuticals has higher revenue and earnings than NLS Pharmaceutics.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
XTL Biopharmaceuticals	$450K	13.79	-$6.97M	-$0.64	N/A
NLS Pharmaceutics	N/A	N/A	-$8.30M	N/A	N/A

In the previous week, XTL Biopharmaceuticals had 1 more articles in the media than NLS Pharmaceutics. MarketBeat recorded 1 mentions for XTL Biopharmaceuticals and 0 mentions for NLS Pharmaceutics. XTL Biopharmaceuticals' average media sentiment score of 0.00 equaled NLS Pharmaceutics'average media sentiment score.

Company	Overall Sentiment
XTL Biopharmaceuticals	Neutral
NLS Pharmaceutics	Neutral

NLS Pharmaceutics has a consensus price target of $23.00, suggesting a potential upside of 518.28%. Given NLS Pharmaceutics' stronger consensus rating and higher probable upside, analysts plainly believe NLS Pharmaceutics is more favorable than XTL Biopharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
XTL Biopharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
NLS Pharmaceutics	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

XTL Biopharmaceuticals has a beta of 1.45, suggesting that its stock price is 45% more volatile than the broader market. Comparatively, NLS Pharmaceutics has a beta of 0.93, suggesting that its stock price is 7% less volatile than the broader market.

Summary

XTL Biopharmaceuticals beats NLS Pharmaceutics on 6 of the 9 factors compared between the two stocks.

Get XTL Biopharmaceuticals News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding XTLB and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

XTLB vs. The Competition

Export

Metric	XTL Biopharmaceuticals	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$6.20M	$3.05B	$6.84B	$12.25B
Dividend Yield	N/A	2.04%	2.67%	9.42%
P/E Ratio	-4.41	19.90	26.81	23.78
Price / Sales	13.79	779.01	576.73	113.34
Price / Cash	N/A	28.08	50.60	60.45
Price / Book	-23.50	4.20	10.42	6.08
Net Income	-$6.97M	$65.94M	$3.60B	$331.73M
7 Day Performance	-0.35%	-2.68%	-1.97%	-1.78%
1 Month Performance	1.08%	-3.09%	-0.84%	-3.04%
1 Year Performance	N/A	10.34%	18.84%	14.19%

XTL Biopharmaceuticals Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
XTLB XTL Biopharmaceuticals	0.384 of 5 stars	$2.82 -3.4%	N/A	N/A	$6.20M	$450K	N/A	N/A	Gap Down
GRML Greenland Mines Ltd. Common Stock	0.2467 of 5 stars	$0.18 +0.9%	N/A	-83.5%	$24.88M	N/A	N/A	5	Gap Up
MRKR Marker Therapeutics	2.3497 of 5 stars	$1.41 -2.1%	$10.00 +609.2%	-21.5%	$24.01M	$3.55M	N/A	60	Positive News
VYNE VYNE Therapeutics	1.0521 of 5 stars	$0.76 +6.5%	N/A	-19.9%	$23.71M	$454K	N/A	30	News Coverage Gap Down
TXMD TherapeuticsMD	0.6546 of 5 stars	$1.94 -1.5%	N/A	+77.2%	$22.80M	$3.02M	32.33	420

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:XTLB) was last updated on 7/23/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

XTL Biopharmaceuticals (XTLB) Competitors

XTLB vs. GRML, MRKR, VYNE, TXMD, and NCEL

How does XTL Biopharmaceuticals compare to Greenland Mines Ltd. Common Stock?

Summary

How does XTL Biopharmaceuticals compare to Marker Therapeutics?

Summary

How does XTL Biopharmaceuticals compare to VYNE Therapeutics?

Summary

How does XTL Biopharmaceuticals compare to TherapeuticsMD?

Summary

How does XTL Biopharmaceuticals compare to NLS Pharmaceutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

XTLB vs. The Competition

XTL Biopharmaceuticals Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

XTL Biopharmaceuticals (XTLB) Competitors

XTLB vs. GRML, MRKR, VYNE, TXMD, and NCEL

How does XTL Biopharmaceuticals compare to Greenland Mines Ltd. Common Stock?

Is XTLB or GRML more profitable?

Do analysts rate XTLB or GRML?

Which has stronger earnings & valuation, XTLB or GRML?

Do insiders and institutionals have more ownership in XTLB or GRML?

Which has more volatility and risk, XTLB or GRML?

Does the media refer more to XTLB or GRML?

Summary

How does XTL Biopharmaceuticals compare to Marker Therapeutics?

Is XTLB or MRKR more profitable?

Which has stronger valuation and earnings, XTLB or MRKR?

Do insiders & institutionals have more ownership in XTLB or MRKR?

Which has more risk and volatility, XTLB or MRKR?

Do analysts prefer XTLB or MRKR?

Does the media refer more to XTLB or MRKR?

Summary

How does XTL Biopharmaceuticals compare to VYNE Therapeutics?

Is XTLB or VYNE more profitable?

Do analysts prefer XTLB or VYNE?

Do institutionals and insiders have more ownership in XTLB or VYNE?

Which has more risk & volatility, XTLB or VYNE?

Which has better earnings & valuation, XTLB or VYNE?

Does the media refer more to XTLB or VYNE?

Summary

How does XTL Biopharmaceuticals compare to TherapeuticsMD?

Is XTLB or TXMD more profitable?

Which has better valuation and earnings, XTLB or TXMD?

Which has more volatility and risk, XTLB or TXMD?

Do analysts recommend XTLB or TXMD?

Do institutionals & insiders believe in XTLB or TXMD?

Does the media favor XTLB or TXMD?

Summary

How does XTL Biopharmaceuticals compare to NLS Pharmaceutics?

Is XTLB or NCEL more profitable?

Do insiders & institutionals have more ownership in XTLB or NCEL?

Which has higher earnings and valuation, XTLB or NCEL?

Does the media favor XTLB or NCEL?

Do analysts prefer XTLB or NCEL?

Which has more volatility and risk, XTLB or NCEL?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

XTLB vs. The Competition

XTL Biopharmaceuticals Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools